Comparative Pharmacology
Head-to-head clinical analysis: ELELYSO versus REVCOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELELYSO versus REVCOVI.
ELELYSO vs REVCOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human glucocerebrosidase; hydrolyzes glucocerebroside to glucose and ceramide, reducing accumulated glucocerebroside in lysosomes of macrophages.
Recombinant adenosine deaminase (ADA) enzyme replacement therapy; degrades adenosine and deoxyadenosine, reducing toxic metabolites and restoring immune function.
60 U/kg administered intravenously over 60 minutes every 2 weeks.
25 mg/kg body weight administered intramuscularly once weekly.
None Documented
None Documented
Mean terminal elimination half-life ranges from 6.1 to 8.9 minutes after intravenous infusion; rapid clearance due to receptor-mediated uptake.
Terminal elimination half-life is approximately 3-6 months (mean ~100 days) in patients with PEG-ADA deficiency; clinical context: sustained enzyme replacement allows weekly or biweekly dosing.
Primarily catabolized via peptide hydrolysis; renal excretion of small peptide fragments and amino acids; less than 1% excreted unchanged in urine.
Renal excretion of unchanged drug and metabolites: approximately 100% eliminated renally; no significant biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy